COGENT BIOSCIENCES INC

COGTNASDAQ

🏆 #1045 by market capEarnings Nov 6US Equity

$38.07▼ $0.62 (−1.63%)

Live

1h▼ 1.2%

24h▼ 1.6%

7d▼ 9.9%

14d▼ 3.8%

30d▲ 1.7%

1y▲ 229.6%

🏦Market Cap

$6.50B

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $37.85 – $38.67
52-Week Range: $11.41 – $43.73
Volume: $2.74B
Avg Volume: $1.84B
Shares Outstanding: 170.9M
Next Earnings: Oct 19, 2026

Fundamentals Snapshot

Annual Revenue: $428M
Last Q Revenue: $110M
P/E Ratio: -12.9
P/S Ratio: 0.0x
EPS (TTM): $-2.21
Dividend Yield: 0.00%

Why Investors Own COGT

✓High-growth profile — revenue up +19.8% YoY with expanding US Equity exposure.
✓Healthy economics — 51% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$428M▲ +17.8% YoY

Gross Margin (TTM)

51.4%▲ +0.4% YoY

Operating Income (TTM)

$159M▲ +17.8% YoY

Free Cash Flow (TTM)

$36M▲ +17.8% YoY

About COGENT BIOSCIENCES INC

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

🦦